Search Results
Apr 07, 2026, 10:00 ET ScribeAI Rebrands as CareBeam to Fix Healthcare's Documentation, Coding, and Revenue Problem
platform generates specialty-aware clinical notes in real time, audits charts automatically for coding accuracy, surfaces E/M level recommendations and ICD-10 mappings, and gives providers on-demand access to clinical guidance, all delivered natively inside the EHRs they already use. CareBeam is currently
More news about: CareBeam
Apr 02, 2026, 08:00 ET Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
Mini-International Neuropsychiatric Interview (MINI, a structured diagnostic interview used to screen for and diagnose psychiatric disorders using DSM/ICD criteria), the Company identified signals that could indicate a potential development path for LPCN 1154.Table: Placebo-Adjusted HAM-D17 Score
More news about: Lipocine Inc.
Apr 01, 2026, 06:00 ET Corti Ships Symphony for Medical Coding with more than 25% Accuracy Edge Over OpenAI and Anthropic
It is the first coding system designed to operate across both US diagnosis coding (ICD-10-CM) and procedure coding (ICD-10-PCS, CPT) and European coding environments without the need for local retraining.ICD-10, maintained by the WHO, is currently available in beta as Corti expands across priority
More news about: Corti
Apr 01, 2026, 06:00 ET Corti Ships Symphony for Medical Coding with more than 25% Accuracy Edge Over OpenAI and Anthropic
It is the first coding system designed to operate across both US diagnosis coding (ICD-10-CM) and procedure coding (ICD-10-PCS, CPT) and European coding environments without the need for local retraining.ICD-10, maintained by the WHO, is currently available in beta as Corti expands across priority
More news about: Corti
Mar 31, 2026, 12:05 ET Grand View Research Launches Advanced U.S. Healthcare Facility Mapping & Intelligence Platform to Enable Data-Driven Decision Making Across the Healthcare Ecosystem
provider optimization and payer-provider strategy discussions.Diagnosis-Level Claims BenchmarkingUsing ICD-10 G47.33 for obstructive sleep apnea, a consulting team evaluated how diagnosis activity was distributed across U.S. hospitals.The
More news about: Grand View Research, Inc.
Mar 26, 2026, 09:42 ET OpenEvidence launches Coding Intelligence™ to help physicians capture every dollar they've earned
be sequenced correctly before the claim goes out - exactly the way an experienced biller would.ICD-10 diagnosis suggestions that reflect actual complexity of the encounter. ICD-10 diagnosis suggestions are surfaced automatically — no manual lookup, no searching for the most specific code
More news about: OpenEvidence
Mar 25, 2026, 08:30 ET Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
Registrational Continuous Renal Replacement Therapy) study. An ICD-10 procedural code, XY0YX37, has been issued for the extracorporeal introduction of nafamostat. The ICD-10 code is a specific/billable code that can be used to indicate a procedure. LTX-608 is a proprietary
More news about: Talphera, Inc.
Mar 23, 2026, 09:00 ET Medtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing
left-ventricular pacing to further improve patient outcomes.The OmniaSecure defibrillation lead connects to an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) to treat potentially life-threatening ventricular tachyarrhythmias, ventricular fibrillation
More news about: Medtronic plc
Mar 23, 2026, 08:30 ET Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Registrational Continuous Renal Replacement Therapy) study. An ICD-10 procedural code, XY0YX37, has been issued for the extracorporeal introduction of nafamostat. The ICD-10 code is a specific/billable code that can be used to indicate a procedure. LTX-608 is a proprietary
More news about: Talphera, Inc.
Mar 19, 2026, 05:03 ET RIMAN impulsa a la acción en la Convención de América del Norte de 2026
norteamericano.Uno de los aspectos más destacados de la convención fue la introducción de los productos para el cuidado de la piel recientemente actualizados ICD Radiansome™100. El acceso exclusivo de RIMAN a una forma patentada de síntesis de liposomas, conocida como Microfluidizer Processor, permitió la dedicación
More news about: RIMAN Inc.
Mar 18, 2026, 16:05 ET Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026
CRRT (Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy) study. An ICD-10 procedural code, XY0YX37, has been issued for the extracorporeal introduction of nafamostat. The ICD-10 code is a specific/billable code that can be used to indicate a procedure. LTX-608 is a proprietary
More news about: Talphera, Inc.
Mar 16, 2026, 03:02 ET Cynosure Lutronic Perkuat Posisi di Asia Pasifik -- Kawasan Perangkat Estetika Medis dengan Pertumbuhan Tercepat di Dunia, Melalui Perolehan Dua Izin Regulasi Clarity II™ di Tiongkok dan Jepang pada Februari 2026
CEO, Cynosure Lutronic.Tiongkok: Persetujuan Regulasi Di Tiongkok, Clarity II™ (dipasarkan dengan nama CLARITY II™ ICD) memperoleh izin untuk digunakan di institusi medis pada 12 Februari 2026.Nama Produk: Clarity II™Indikasi
More news about: Cynosure Lutronic
Mar 13, 2026, 05:42 ET RIMAN donne l'impulsion à la convention 2026 Amérique du Nord
l'accélération de la dynamique du marché nord-américain.L'un des points forts de la convention a été l'introduction des produits de soins de la peau ICD Radiansome™100, récemment améliorés. L'accès exclusif de RIMAN à une forme brevetée de production des liposomes, connue sous le nom de Microfluidizer
More news about: RIMAN Inc.
Mar 12, 2026, 03:20 ET RIMAN bringt Schwung in die 2026 North America Convention
deutlich die zunehmende Dynamik des nordamerikanischen Marktes.Ein wichtiger Höhepunkt des Kongresses war die Einführung der neu überarbeiteten ICD Radiansome™100 Hautpflegeprodukte. RIMANs exklusiver Zugang zu einer patentierten Form der Liposomensynthese, bekannt als Microfluidizer Processor, ermöglichte
More news about: RIMAN Inc.
Mar 10, 2026, 21:52 ET RIMAN Ignites Momentum at 2026 North America Convention
demonstrated the accelerating momentum of the North American market.A key highlight of the convention was the introduction of the newly upgraded ICD Radiansome™100 skincare products. RIMAN's exclusive access to a patented form of liposome synthesis, known as the Microfluidizer Processor, allowed for
More news about: RIMAN Inc.
Mar 10, 2026, 21:22 ET RIMAN Ignites Momentum at 2026 North America Convention
demonstrated the accelerating momentum of the North American market.A key highlight of the convention was the introduction of the newly upgraded ICD Radiansome™100 skincare products. RIMAN's exclusive access to a patented form of liposome synthesis, known as the Microfluidizer Processor, allowed for
More news about: RIMAN Inc.
Mar 09, 2026, 01:35 ET Cynosure Lutronic củng cố vị thế tại khu vực APAC -- khu vực tăng trưởng nhanh nhất thế giới về thiết bị thẩm mỹ y khoa, với việc Clarity II™ được phê duyệt pháp lý tại Trung Quốc và Nhật Bản, tháng 2 năm 2026
lý Tại Trung Quốc, Clarity II (được tiếp thị với tên CLARITY II ICD) đã nhận được phê duyệt pháp lý để sử dụng tại các cơ sở y tế kể từ ngày 12 tháng 2 năm 2026. Tên sản phẩm: Clarity II ICDCác chỉ định được phê duyệt:Laser 755nm
More news about: Cynosure Lutronic
Mar 05, 2026, 03:24 ET RIMAN galardonado con el PREMIO iF DESIGN 2026, fortaleciendo su liderazgo de marca global
RIMAN, una marca coreana premium de cuidado de la piel y bienestar, ha anunciado que su línea ICD Dermatology Line, con boosters, sueros y cremas, ha recibido el PREMIO iF DESIGN 2026 en la categoría de DISEÑO de envases. El empaque reimagina el ingrediente
More news about: RIMAN Inc.
Mar 03, 2026, 11:16 ET New Research from The Fuchsia Tent Shows Making Midlife Women Visible in Employer Health Data Could Save U.S. Companies $26.6B
that population being in some stage of the menopausal transition. Symptoms like anxiety, insomnia, joint pain, and cognitive changes are captured in ICD-10 coding as standalone conditions and never linked to menopause, leading to widespread mis- and underdiagnosis that costs U.S. employers an estimated
More news about: The Fuchsia Tent
Mar 03, 2026, 05:33 ET RIMAN、iF DESIGN AWARD 2026を受賞 ― グローバルブランドとしてのリーダーシップを強化
韓国のプレミアム・スキンケアおよびウェルネス・ブランドであるRIMANは、ブースター、美容液、クリームを特徴とするICD Derma 製品ライン（ICDダーマライン、グローバルでは「ICD Dermatology 製品ライン」として展開）が、iF DESIGN AWARD 2026のパッケージデザイン部門を受賞しました。このパッケージは、RIMANの代表的成分であるGiant BYoungPool™（Giant Centella Asiatica）を、ミニマルかつ洗練されたデザインで再構築したものです。Lava
More news about: RIMAN Inc.
Mar 02, 2026, 23:09 ET Cynosure Lutronic、Clarity II™の中国・日本における薬事承認取得により、世界で最も急成長している美容医療機器市場であるAPACでの競争力をさらに強化（2026年2月）
Lutronicの競争力が着実に高まっていることを示すものです」と述べています。中国：薬事承認中国において、Clarity II（CLARITY II ICDとして販売）は、2026年2月12日付で医療機関での使用に関する薬事承認を取得しました。製品名：Clarity II ICD承認された適応：755nmレーザー：頬のしわを軽減する用途で承認を取得1064nmレーザー：ムダ毛を減らす用途で承認を取得今回の承認により、中国の規制下にある臨床現場において、複数の治療用途に対して単一の統合プラットフォームを使用することが正式に認められました。日本：薬事承認日本において、Clarity
More news about: Cynosure Lutronic
Mar 02, 2026, 08:30 ET Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
NEPHRO CRRT (Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy) study. An ICD-10 procedural code, XY0YX37, has been issued for the extracorporeal introduction of nafamostat. The ICD-10 code is a specific/billable code that can be used to indicate a procedure. LTX-608 is a proprietary
More news about: Talphera, Inc.
Feb 27, 2026, 10:13 ET RIMAN recibe el iF DESIGN AWARD 2026 y consolida su liderazgo global
RIMAN, marca coreana prémium de cuidado de la piel y bienestar, anunció que su línea ICD Dermatology, que incluye potenciadores, sérums y cremas, recibió el premio iF DESIGN AWARD 2026 en la categoría de Diseño de Empaque. El empaque reinventa
More news about: RIMAN Inc.
Feb 27, 2026, 05:49 ET Cynosure Lutronic旗下Clarity II™獲中日雙重監管批准 -- 強化其在亞太醫美設備市場的競爭力
Lutronic在亞太地區的市場競爭力正持續提升。」中國：監管許可在中國，Clarity II（商品名稱為CLARITY II ICD）已獲得監管批准，自2026年2月12日起可在醫療機構使用。 產品名稱：Clarity II ICD 批准適應症： 755nm激光 - 獲准用於改善面頰部皺紋1064nm激光 - 獲准用於去除體部多餘毛髮該許可明確，該單一集成平台可在國內合規臨床環境中，用於多種治療場景。日本：監管許可在日本，Clarity
More news about: Cynosure Lutronic
Feb 27, 2026, 04:21 ET RIMAN wird mit dem iF DESIGN AWARD 2026 ausgezeichnet und stärkt damit seine globale Markenführerschaft
RIMAN, eine koreanische Premium-Hautpflege- und Wellness-Marke, gab bekannt, dass ihre ICD Dermatology Line mit Boostern, Seren und Cremes den iF DESIGN AWARD 2026 in der Kategorie Verpackungsdesign erhalten hat. Die Verpackung stellt den charakteristischen
More news about: RIMAN Inc.